Viracta Therapeutics (VIRX) Competitors $0.25 +0.02 (+7.43%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VIRX vs. OTLK, ANEB, SRZN, VRCA, IXHL, RAPT, RNXT, PMN, LIAN, and NXTCShould you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Outlook Therapeutics (OTLK), Anebulo Pharmaceuticals (ANEB), Surrozen (SRZN), Verrica Pharmaceuticals (VRCA), Incannex Healthcare (IXHL), RAPT Therapeutics (RAPT), RenovoRx (RNXT), ProMIS Neurosciences (PMN), LianBio (LIAN), and NextCure (NXTC). These companies are all part of the "pharmaceutical products" industry. Viracta Therapeutics vs. Outlook Therapeutics Anebulo Pharmaceuticals Surrozen Verrica Pharmaceuticals Incannex Healthcare RAPT Therapeutics RenovoRx ProMIS Neurosciences LianBio NextCure Outlook Therapeutics (NASDAQ:OTLK) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment. Does the media prefer OTLK or VIRX? In the previous week, Outlook Therapeutics had 2 more articles in the media than Viracta Therapeutics. MarketBeat recorded 2 mentions for Outlook Therapeutics and 0 mentions for Viracta Therapeutics. Outlook Therapeutics' average media sentiment score of 0.00 equaled Viracta Therapeutics'average media sentiment score. Company Overall Sentiment Outlook Therapeutics Neutral Viracta Therapeutics Neutral Do analysts rate OTLK or VIRX? Outlook Therapeutics presently has a consensus target price of $42.34, indicating a potential upside of 2,780.47%. Viracta Therapeutics has a consensus target price of $5.00, indicating a potential upside of 1,900.00%. Given Outlook Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Outlook Therapeutics is more favorable than Viracta Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Viracta Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is OTLK or VIRX more profitable? Outlook Therapeutics' return on equity of 0.00% beat Viracta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Outlook TherapeuticsN/A N/A -160.88% Viracta Therapeutics N/A -1,899.61%-114.21% Do insiders & institutionals have more ownership in OTLK or VIRX? 11.2% of Outlook Therapeutics shares are owned by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are owned by institutional investors. 3.4% of Outlook Therapeutics shares are owned by insiders. Comparatively, 10.7% of Viracta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, OTLK or VIRX? Outlook Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Which has better earnings & valuation, OTLK or VIRX? Viracta Therapeutics is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOutlook TherapeuticsN/AN/A-$58.98M-$10.70-0.14Viracta TherapeuticsN/AN/A-$51.06M-$1.10-0.23 Does the MarketBeat Community prefer OTLK or VIRX? Outlook Therapeutics received 132 more outperform votes than Viracta Therapeutics when rated by MarketBeat users. However, 72.50% of users gave Viracta Therapeutics an outperform vote while only 70.93% of users gave Outlook Therapeutics an outperform vote. CompanyUnderperformOutperformOutlook TherapeuticsOutperform Votes16170.93% Underperform Votes6629.07% Viracta TherapeuticsOutperform Votes2972.50% Underperform Votes1127.50% SummaryOutlook Therapeutics and Viracta Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRX vs. The Competition Export to ExcelMetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.94M$6.71B$5.23B$9.28BDividend YieldN/A3.00%5.12%4.28%P/E Ratio-0.2310.6387.7017.30Price / SalesN/A196.091,167.68119.60Price / CashN/A57.1543.2337.83Price / Book0.765.164.834.93Net Income-$51.06M$151.58M$120.55M$225.42M7 Day Performance21.07%4.14%2.86%4.14%1 Month Performance61.29%-3.97%19.71%1.15%1 Year Performance-50.10%10.34%30.57%16.99% Viracta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRXViracta Therapeutics2.6091 of 5 stars$0.25+7.4%$5.00+1,900.0%-50.1%$9.94MN/A-0.2320OTLKOutlook Therapeutics1.8884 of 5 stars$1.43-3.7%$42.34+2,871.4%-82.6%$33.72MN/A-0.1320ANEBAnebulo Pharmaceuticals2.0092 of 5 stars$1.30-7.1%$8.00+515.4%-37.7%$33.71MN/A-4.674News CoverageGap DownHigh Trading VolumeSRZNSurrozen1.1219 of 5 stars$10.00+1.5%N/A+46.1%$32.50M$10M0.0042Gap DownVRCAVerrica Pharmaceuticals4.7228 of 5 stars$0.71-6.4%$9.50+1,234.1%-89.9%$32.47M$5.12M-0.4040IXHLIncannex HealthcareN/A$1.83-1.6%N/A-55.5%$32.29M$86,000.00-1.343RAPTRAPT Therapeutics4.7876 of 5 stars$0.91-0.3%$9.50+946.9%-92.7%$31.72M$1.53M-0.3380News CoverageRNXTRenovoRx1.2638 of 5 stars$1.27-0.8%$6.50+411.8%+25.2%$30.48MN/A-2.256Positive NewsGap UpPMNProMIS Neurosciences0.6492 of 5 stars$0.91-2.7%N/A-12.1%$29.58M$10,000.00-9.306Positive NewsLIANLianBioN/A$0.27flat$3.50+1,194.4%-94.2%$29.22MN/A-0.33110Gap DownNXTCNextCure4.2482 of 5 stars$1.02-5.6%$4.00+292.2%-24.5%$28.57MN/A0.0090 Related Companies and Tools Related Companies OTLK Alternatives ANEB Alternatives SRZN Alternatives VRCA Alternatives IXHL Alternatives RAPT Alternatives RNXT Alternatives PMN Alternatives LIAN Alternatives NXTC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VIRX) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIRX Stock Alerts